Effects of an SGLT2 inhibitor on the salt sensitivity of blood pressure and sympathetic nerve activity in a nondiabetic rat model of chronic kidney disease.
Blood pressure
Chronic kidney disease
Rat
Salt
Sodium-glucose cotransporter 2 inhibitor
Sympathetic nerve activity
Journal
Hypertension research : official journal of the Japanese Society of Hypertension
ISSN: 1348-4214
Titre abrégé: Hypertens Res
Pays: England
ID NLM: 9307690
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
29
09
2019
accepted:
23
12
2019
revised:
09
12
2019
pubmed:
16
2
2020
medline:
17
8
2021
entrez:
16
2
2020
Statut:
ppublish
Résumé
The glucose-lowering effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors is reduced in patients with diabetes who have chronic kidney disease (CKD). In the present study, we examined the effect of an SGLT2 inhibitor on the salt sensitivity of blood pressure (BP), circadian rhythm of BP, and sympathetic nerve activity (SNA) in nondiabetic CKD rats. Uninephrectomized Wistar rats were treated with adenine (200 mg/kg/day) for 14 days. After stabilization with a normal-salt diet (NSD, 0.3% NaCl), a high-salt diet (HSD, 8% NaCl) was administered. Mean arterial pressure (MAP) was continuously monitored using a telemetry system. We also analyzed the low frequency (LF) of systolic arterial pressure (SAP), which reflects SNA. In adenine-induced CKD rats, HSD consumption for 5 days significantly increased the mean MAP from 106 ± 2 to 148 ± 3 mmHg. However, MAP was decreased to 96 ± 3 mmHg within 24 h after switching back to a NSD (n = 7). Treatment with an SGLT2 inhibitor, luseogliflozin (10 mg/kg/day, p.o., n = 7), significantly attenuated the HSD-induced elevation of MAP, which was associated with a reduction in LF of SAP. These data suggest that treatment with an SGLT2 inhibitor attenuates the salt sensitivity of BP, which is associated with SNA inhibition in nondiabetic CKD rats.
Identifiants
pubmed: 32060381
doi: 10.1038/s41440-020-0410-8
pii: 10.1038/s41440-020-0410-8
doi:
Substances chimiques
Sodium Chloride, Dietary
0
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
492-499Références
Yamazaki D, Hitomi H, Nishiyama A. Hypertension with diabetes mellitus complications. Hypertension Res. 2018;41:147–56.
doi: 10.1038/s41440-017-0008-y
List JF, Whaley JM. Glucose dynamics and mechanistic implications of SGLT2inhibitors in animals and humans. Kidney Int Suppl. 2011. https://doi.org/10.1038/ki.2010.512 .
doi: 10.1038/ki.2010.512
Fitchett DH. Empagliflozin and cardio-renal outcomes in patients with type 2 diabetes and cardiovascular disease - implications for clinical practice. Eur Endocrinol. 2018;14:40–9.
doi: 10.17925/EE.2018.14.2.40
Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME Study. Diabetes care 2016;39:717–25.
doi: 10.2337/dc16-0041
Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J. 2016;37:1526–34.
doi: 10.1093/eurheartj/ehv728
Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8:262–75.e269.
doi: 10.1016/j.jash.2014.01.007
Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262–74.
doi: 10.7326/0003-4819-159-4-201308200-00007
Kario K, Okada K, Kato M, Nishizawa M, Yoshida T, Asano T, et al. 24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA Study. Circulation. 2018. https://doi.org/10.1161/circulationaha.118.037076 .
doi: 10.1161/CIRCULATIONAHA.118.037076
Wan N, Rahman A, Hitomi H, Nishiyama A. The effects of sodium-glucose cotransporter 2 inhibitors on sympathetic nervous activity. Front Endocrinol. 2018;9:421.
Rahman A, Fujisawa Y, Nakano D, Hitomi H, Nishiyama A. Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats. Clin Exp Pharmacol Physiol. 2017;44:522–5.
doi: 10.1111/1440-1681.12725
Maegawa H, Tobe K, Tabuchi H, Nakamura I. Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice. Expert Opin Pharmacother. 2016;17:1985–94.
doi: 10.1080/14656566.2016.1217994
Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes, Obes Metab. 2015;17:1180–93.
doi: 10.1111/dom.12572
Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes, Obes Metab. 2015;17:936–48.
doi: 10.1111/dom.12503
Sjostrom CD, Johansson P, Ptaszynska A, List J, Johnsson E. Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. Diabetes Vasc Dis Res. 2015;12:352–8.
doi: 10.1177/1479164115585298
Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015;38:355–64.
doi: 10.2337/dc13-2762
Sano M, Chen S, Imazeki H. Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: subanalysis of placebo-controlled, double-blind clinical trials. J Diabetes Investig. 2018;9:638-41.
doi: 10.1111/jdi.12726
Yoshikawa T, Kishi T, Shinohara K, Takesue K, Shibata R, Sonoda N, et al. Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats. Hypertension Res. 2017;40:646–51.
doi: 10.1038/hr.2017.14
Chiba Y, Yamada T, Tsukita S, Takahashi K, Munakata Y, Shirai Y, et al. Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, acutely reduces energy expenditure in BAT via neural signals in mice. PloS ONE. 2016;11:e0150756.
doi: 10.1371/journal.pone.0150756
Matthews VB, Elliot RH, Rudnicka C, Hricova J, Herat L, Schlaich MP. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. J Hypertens. 2017;35:2059–68.
doi: 10.1097/HJH.0000000000001434
Jordan J, Tank J, Heusser K, Heise T, Wanner C, Heer M, et al. The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus. J Am Soc Hypertens. 2017;11:604–12.
doi: 10.1016/j.jash.2017.07.005
Heise T, Jordan J, Wanner C, Heer M, Macha S, Mattheus M, et al. Pharmacodynamic effects of single and multiple doses of empagliflozin in patients with type 2 diabetes. Clin Therapeutics 2016;38:2265–76.
doi: 10.1016/j.clinthera.2016.09.001
Guyenet PG. Putative mechanism of salt-dependent neurogenic hypertension: cell-autonomous activation of organum vasculosum laminae terminalis neurons by hypernatremia. Hypertension. 2017;69:20–2.
doi: 10.1161/HYPERTENSIONAHA.116.08470
Kelly MS, Lewis J, Huntsberry AM, Dea L, Portillo I. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Postgrad Med. 2019;131:31–42.
doi: 10.1080/00325481.2019.1549459
Oliveira-Sales EB, Toward MA, Campos RR, Paton JF. Revealing the role of the autonomic nervous system in the development and maintenance of Goldblatt hypertension in rats. Auton Neurosci. 2014;183:23–9.
doi: 10.1016/j.autneu.2014.02.001
Kimura G, Frem GJ, Brenner BM. Renal mechanisms of salt sensitivity in hypertension. Curr Opin Nephrol Hypertens. 1994;3:1–12.
doi: 10.1097/00041552-199401000-00001
Kimura G. Glomerular function reserve and sodium sensitivity. Clin Exp Nephrol. 2005;9:102–13.
doi: 10.1007/s10157-005-0353-z
Takeshige Y, Fujisawa Y, Rahman A, Kittikulsuth W, Nakano D, Mori H, et al. A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats. Hypertens. 2016;39:415–22.
Rahman A, Kittikulsuth W, Fujisawa Y, Sufiun A, Rafiq K, Hitomi H, et al. Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome. J Hypertens. 2016;34:893–906.
doi: 10.1097/HJH.0000000000000871
Ansary TM, Fujisawa Y, Rahman A. Responses of renal hemodynamics and tubular functions to acute sodium-glucose cotransporter 2 inhibitor administration in non-diabetic anesthetized rats. 2017;7:9555.
Fujita M, Fujita T. The role of CNS in the effects of salt on blood pressure. Curr Hypertens Rep. 2016;18:10.
doi: 10.1007/s11906-015-0620-7
Fujita T. Mechanism of salt-sensitive hypertension: focus on adrenal and sympathetic nervous systems. J Am Soc Nephrol. 2014;25:1148–55.
doi: 10.1681/ASN.2013121258
Khawaja Z, Wilcox CS. Role of the kidneys in resistant hypertension. Int J Hypertens. 2011;2011:143471.
doi: 10.4061/2011/143471
Simmonds SS, Lay J, Stocker SD. Dietary salt intake exaggerates sympathetic reflexes and increases blood pressure variability in normotensive rats. Hypertension. 2014;64:583–9.
doi: 10.1161/HYPERTENSIONAHA.114.03250
Nguy L, Johansson ME, Grimberg E, Lundgren J, Teerlink T, Carlstrom M, et al. Rats with adenine-induced chronic renal failure develop low-renin, salt-sensitive hypertension and increased aortic stiffness. Am J Physiol Regulatory, Integr Comp Physiol. 2013;304:R744–52.
doi: 10.1152/ajpregu.00562.2012
Sufiun A, Rafiq K, Fujisawa Y, Rahman A, Mori H, Nakano D, et al. Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats. Hypertension Res. 2015;38:237–43.
doi: 10.1038/hr.2014.173
van den Buuse M. Circadian rhythms of blood pressure and heart rate in conscious rats: effects of light cycle shift and timed feeding. Physiol Behav. 1999;68:9–15.
doi: 10.1016/S0031-9384(99)00148-1
Chang TI, Owens DK, Chertow GM. Lowering blood pressure to lower the risk of cardiovascular events in CKD. Am J Kidney Dis. 2014;63:900–2.
doi: 10.1053/j.ajkd.2014.03.001
McMahon EJ, Bauer JD, Hawley CM, Isbel NM, Stowasser M, Johnson DW, et al. The effect of lowering salt intake on ambulatory blood pressure to reduce cardiovascular risk in chronic kidney disease (LowSALT CKD study): protocol of a randomized trial. BMC Nephrol 2012;13:137.
doi: 10.1186/1471-2369-13-137
Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 2018;137:119–29.
doi: 10.1161/CIRCULATIONAHA.117.028268